ANI Pharmaceuticals (ANIP) and Its Competitors Financial Analysis

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare ANI Pharmaceuticals to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares ANI Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ANI Pharmaceuticals $883.37 million $78.34 million 14.23
ANI Pharmaceuticals Competitors $16.51 billion $3.17 billion 562.76

ANI Pharmaceuticals’ peers have higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals’ peers have a beta of -0.04, suggesting that their average stock price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ANI Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 4 3 0 2.43
ANI Pharmaceuticals Competitors 7844 13796 25806 1039 2.41

ANI Pharmaceuticals currently has a consensus price target of $100.00, suggesting a potential upside of 39.98%. As a group, “Pharmaceuticals” companies have a potential upside of 24.64%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ANI Pharmaceuticals is more favorable than its peers.

Insider & Institutional Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ANI Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 11.22% 28.34% 11.18%
ANI Pharmaceuticals Competitors -2,398.26% -203.62% -15.08%

Summary

ANI Pharmaceuticals beats its peers on 7 of the 13 factors compared.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.